Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

被引:392
作者
Suki, W. N.
Zabaneh, R.
Cangiano, J. L.
Reed, J.
Fischer, D.
Garrett, L.
Ling, B. N.
Chasan-Taber, S.
Dillon, M. A.
Blair, A. T.
Burke, S. K.
机构
[1] Baylor Coll Med, Kidney Inst, Renal Sect, Dept Med, Houston, TX 77054 USA
[2] NW Louisiana Nephrol, Shreveport, LA USA
[3] Jose Cangiano Nephrol, San Juan, PR USA
[4] Nephrol Associates, Columbus, MS USA
[5] Kidney & Hypertens Ctr, Cincinnati, OH USA
[6] Wake Nephrol, Raleigh, NC USA
[7] Mt Kidney Associates, Asheville, NC USA
[8] Genzyme Corp, Cambridge, MA USA
关键词
phosphorus; calcium; hemodialysis; phosphate-binders; sevelamer; mortality;
D O I
10.1038/sj.ki.5002466
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Elevated serum phosphorus and calcium are associated with arterial calcification and mortality in dialysis patients. Unlike calcium-based binders, sevelamer attenuates arterial calcification but it is unknown whether sevelamer affects mortality or morbidity. In a multicenter, randomized, open-label, parallel design trial we compared sevelamer and calcium-based binders on all-cause and cause-specific mortality (cardiovascular, infection, and other) in prevalent hemodialysis patients. A total of 2103 patients were initially randomized to treatment and 1068 patients completed the study. All-cause mortality rates and cause-specific mortality rates were not significantly different. There was a significant age interaction on the treatment effect. Only in patients over 65 years of age was there a significant effect of sevelamer in lowering the mortality rate. There was a suggestion that sevelamer was associated with lower overall, but not cardiovascular-linked, mortality in older patients. We suggest that further research is needed to confirm these findings.
引用
收藏
页码:1130 / 1137
页数:8
相关论文
共 31 条
[1]  
[Anonymous], AMERICAN JOURNAL OF
[2]   Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density [J].
Asmus, HG ;
Braun, J ;
Krause, R ;
Brunkhorst, R ;
Holzer, H ;
Schulz, W ;
Neumayer, HH ;
Raggi, P ;
Bommer, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (08) :1653-1661
[3]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[4]   Impact of aortic stiffness on survival in end-stage renal disease [J].
Blacher, J ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
Safar, ME ;
London, GM .
CIRCULATION, 1999, 99 (18) :2434-2439
[5]   Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease [J].
Blacher, J ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
London, GM .
HYPERTENSION, 2001, 38 (04) :938-942
[6]   Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients [J].
Block, G. A. ;
Raggi, P. ;
Bellasi, A. ;
Kooienga, L. ;
Spiegel, D. M. .
KIDNEY INTERNATIONAL, 2007, 71 (05) :438-441
[7]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[8]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[9]  
Braun J, 2004, CLIN NEPHROL, V62, P104
[10]   Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients [J].
Braun, J ;
Oldendorf, M ;
Moshage, W ;
Heidler, R ;
Zeitler, E ;
Luft, FC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :394-401